Key takeaways from ASX listings for the First Half of 2017
In Australia, the IPO market is well and truly alive and kicking! A total of 55 companies listed onto the ASX in a vibrant start to the 2017 calendar year, listing with a combined market capitalisation of $3,410m. Of those, 23 had beat their IPO price by 30 June 2017, with 5 achieving more than a 100% return.
Here are the results of the 55 floats to take place in the first half of 2017:
|Top Ten IPOs by Market Capitalisation|
|Company||Industry||Market Cap. At IPO
|Bingo Industries Limited||Waste Industries||628||440|
|Oceania Healthcare Limited||Healthcare||445||185|
|Plato Income Maximiser Limited||Financial Services||326||326|
|Moelis Australia Limited||Financial Services||294||59|
|ELMO Software Limited||Technology||108||25|
|ReTech Technology Co., Limited||Technology||108||18|
|Visioneering Technologies, Inc.||Financial Services||83||33|
|Urb Investments Limited||Financial Services||80||80|
|Big River Group Pty Limited||Property||77||17|
|Audinate Group Limited||Tecnology||73||21|
|Source: S&P Capital IQ, William Buck analysis|
2017 so far has been a year of surprises
What were some of the unexpected surprises and key new developments dominating this list of 55 new entrants to the ASX? Perhaps it was the evenness of the spread of value over the new entrants, only $2,222m of the $3,410m in value was attributed to the top 10 listings. Why ‘only’? One of the characteristics of the ASX is its significant segmentation between its larger and smaller cap companies. However, from this list, those outside the top 10 still comprised 35% of the total market value of all the new entrants. To us, this signals that the market currently views positively new ASX listed entrants, the new technologies or products that they seek to commercialize and their ability to disrupt existing and established players.
Another key surprise; only one biotechnology company was amongst the IPOs, whereas biotech’s have previously been an important staple of ASX listings. We have noticed that some biotech’s are now going to the US for funding, where investor knowledge and appetite of such stocks is far greater.
Beyond these points, we have identified 3 key themes in our observations that we believe have specific resonance for the ASX market, and for its future trends ahead:
Market sentiment on the back of recent federal and state-based regulatory reforms has been extremely positive for medicinal cannabis and is emulating the strong, long term stories similar stock have had both Canada and in the US. In Australia, there were 4 new medicinal cannabis listings, and all performed strongly:
|30 June 2017
|The Hydroponics Company||20.0||30.0||50%|
From Lithium to Cobalt
Throughout the first half of the 2017 calendar year a further 16 junior explorers floated onto the ASX. Junior exploration companies have always been a staple of the Australian micro-mid-cap environment, with a strong investor base and established entrepreneurial networks. The theme carried over from 2016 for the six months, was batteries – only with a twist. Lithium, the darling of 2016 was less appealing; in its place cobalt attracted significant interest (Australian Financial Review, if you thought Lithium was exciting, try cobalt – 11 April 2017). As a snapshot, these were highest and lowest performing IPOs of the junior explorers:
|Enterprise||Principal Product(s)||Prospectus Price
|30 June 2017
|Ardea Resources||Cobalt and nickel||20.0||58.0||190%|
Tel Aviv comes to Australia
Also a trend from 2016 was the continuing interest of Israeli-based tech firms in the ASX-listed environment. In the first half of the 2017 calendar year 4 Israeli enterprises successfully listed on the ASX, all promoting advancements to technologies in communications, surveillance and healthcare. Key reasons for the interest include Australia’s technology infrastructure, proximity to Asia and Australia’s credentials known for supporting in capital markets (relative to the US) early stage ventures (AFR – ASX preparing for rush of Israeli tech listings).
About the authors
Nicholas Benbow is a Director at William Buck with a specialisation in providing assurance to clients listing or contemplating listing on the ASX. Over the past 5 years he has worked with numerous enterprises that have either listed or relisted on the ASX.
Liz Smith is a Corporate Advisory Director at William Buck. Liz has extensive experience across mergers and acquisitions, due diligence, valuations and IPO transactions.
The observations, views and thoughts expressed by both authors in this article are their own entirely and do not in any way represent financial advice that should or can be relied upon for investment decision making.